Immuron Ltd Files March 2024 6-K Report

TL;DR

Immuron Ltd dropped its March 6-K, check for new announcements.

AI Summary

Immuron Limited filed a Form 6-K on March 7, 2024, reporting on its activities for the month of March 2024. The filing indicates that the company is a foreign private issuer and is furnishing information to the SEC under Rule 13a-16 or 15d-16. The report includes one published announcement.

Why It Matters

This filing provides an update on Immuron Limited's regulatory disclosures for March 2024, which is important for investors tracking the company's compliance and public statements.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of information by a foreign private issuer and does not contain significant new financial or operational developments.

Key Players & Entities

• Immuron Limited (company) — Registrant
• 0001213900-24-020599 (filing_id) — Accession Number
• March 2024 (date) — Reporting period
• Rule 13a-16 (regulation) — SEC Filing Rule
• Rule 15d-16 (regulation) — SEC Filing Rule

FAQ

Filing Documents

• ea0201341-6k_immuron.htm (6-K) — 13KB
• ea0201341ex99-1_immuron.htm (EX-99.1) — 63KB
• image_001.jpg (GRAPHIC) — 1KB
• ex99-1_001.jpg (GRAPHIC) — 5KB
• ex99-1_002.jpg (GRAPHIC) — 7KB
• ex99-1_003.jpg (GRAPHIC) — 3KB
• 0001213900-24-020599.txt ( ) — 100KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of March 2024 Commission File Number: 001-38104 IMMURON LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- IMMURON LIMITED EXPLANATORY NOTE Immuron Limited (the “Company”) published one announcement (the “Public Notices”) to the Australian Securities Exchange on March 7, 2024 titled: - “Travelan to progress to Phase 3 Clinical Trials in the US” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Travelan to progress to Phase 3 Clinical Trials in the US 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMURON LIMITED Date: March 7, 2024 By: /s/ Phillip Hains Phillip Hains Company Secretary 3

View Full Filing

View this 6-K filing on SEC EDGAR